Vantage logo

Approaching datasets for big pharma

J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts. 

Vantage logo

UCB leads the stale scale

Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.

Vantage logo

Nkarta goes back to basics

After a hiatus Nkarta comes back with a new lymphodepletion regimen to boost its lead Car-NK therapy.